These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2618884)

  • 1. [Intermittent intravenous high-dose cyclophosphamide therapy for advanced prostatic cancer with distant metastasis].
    Kyakuno M; Yamaguchi S; Matsumiya K; Osafune M
    Hinyokika Kiyo; 1989 Nov; 35(11):1865-9. PubMed ID: 2618884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
    Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
    Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of stage D prostate cancer patients with hormones in combination with cyclophosphamide].
    Fujii A; Yasuno H; Kawaida T; Nakamura I
    Hinyokika Kiyo; 1986 Nov; 32(11):1713-7. PubMed ID: 2435128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer.
    Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Cancer Res; 1973 Oct; 33(10):2218-20. PubMed ID: 4741927
    [No Abstract]   [Full Text] [Related]  

  • 6. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
    Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
    Feng J; Zheng X; Dai A
    Zhonghua Zhong Liu Za Zhi; 1998 Nov; 20(6):468-70. PubMed ID: 10920949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
    Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
    Dawson NA; Conaway M; Halabi S; Winer EP; Small EJ; Lake D; Vogelzang NJ
    Cancer; 2000 Feb; 88(4):825-34. PubMed ID: 10679652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
    Miglietta L; Cannobbio L; Boccardo F
    Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliative chemotherapy with trofosfamide in advanced prostate cancer.
    Salminen EK; Sundström J; Nikkanen V
    Anticancer Res; 2006; 26(1B):539-42. PubMed ID: 16739316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
    Solit DB; Morris M; Slovin S; Curley T; Schwartz L; Larson S; Kattan MW; Hartley-Asp B; Scher HI; Kelly WK
    Cancer; 2003 Nov; 98(9):1842-8. PubMed ID: 14584065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate dose single agent cyclophosphamide chemotherapy of advanced breast cancer.
    Bramwell VH; Howell A; Anderson H; Rankin EM
    Clin Oncol; 1983 Sep; 9(3):251-6. PubMed ID: 6617000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.